13,150 Shares in Ralliant Corporation $RAL Bought by Osborne Partners Capital Management LLC

Osborne Partners Capital Management LLC purchased a new position in shares of Ralliant Corporation (NYSE:RAL) during the third quarter, Holdings Channel.com reports. The firm purchased 13,150 shares of the company’s stock, valued at approximately $575,000.

Other hedge funds also recently modified their holdings of the company. Dodge & Cox bought a new position in Ralliant during the second quarter worth $523,571,000. Viking Global Investors LP acquired a new position in shares of Ralliant during the second quarter valued at about $257,200,000. State Street Corp acquired a new position in shares of Ralliant during the second quarter valued at about $213,096,000. Flossbach Von Storch SE acquired a new position in Ralliant during the 2nd quarter worth approximately $198,077,000. Finally, Norges Bank acquired a new position in Ralliant during the 2nd quarter worth approximately $108,453,000.

Ralliant Price Performance

Shares of RAL stock opened at $53.79 on Thursday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.03 and a current ratio of 1.49. The firm has a 50-day moving average price of $50.49. Ralliant Corporation has a one year low of $40.70 and a one year high of $55.08. The stock has a market capitalization of $6.07 billion and a P/E ratio of 42.35.

Ralliant (NYSE:RAL) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.02. The firm had revenue of $529.10 million during the quarter, compared to the consensus estimate of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 23rd. Stockholders of record on Monday, December 8th were given a $0.05 dividend. The ex-dividend date was Monday, December 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Ralliant’s payout ratio is 15.75%.

Analyst Ratings Changes

RAL has been the subject of a number of research reports. Truist Financial began coverage on Ralliant in a research note on Friday, December 12th. They issued a “buy” rating and a $62.00 price objective for the company. Royal Bank Of Canada lifted their price target on shares of Ralliant from $45.00 to $52.00 and gave the company a “sector perform” rating in a research report on Friday, November 7th. Citigroup raised shares of Ralliant from a “neutral” rating to a “buy” rating and raised their price objective for the company from $53.00 to $61.00 in a research note on Monday, December 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Ralliant in a report on Monday, December 29th. Finally, Oppenheimer upped their target price on shares of Ralliant from $55.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $58.00.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.